IDH2 mutations in acute myeloid leukemia.

Abstract excerpt

Advances in the treatment of acute myeloid leukemia (AML) over the last 40 years have been limited. With an improved understanding of the pathophysiology of the disease, the advent of new treatment options has enriched the armamentarium of the physician to combat the disease. Mutations of the isocitrate dehydrogenase (IDHs) genes are common in AML and occur in 20-30% of cases. These mutations lead to DNA...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aminopyridines
• Share to Antineoplastic Agents
• Share to Isocitrate Dehydrogenase